metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
malignant mesothelioma (mMS) - 1st line (L1) malignant mesothelioma (mMS) - 1st line (L1)
versus pemetrexed plus platin
	nivolumab plus ipilimumab
	CheckMate 743, 2021 Lancet 2021 Jan 30;397(10272):375-386. Lung Cancer 2022; 167:8-16-. Ann Oncol 2022; 33:488-499-. NCT02899299	RCT	malignant mesothelioma (mMS) - 1st line (L1)	nivolumab plus ipilimumab	cisplatin or carboplatin plus pemetrexed	first-line treatment of patients with unresectable malignant pleural mesothelioma	303 / 302	some concern	conclusif	demonstrated 26 % decrease in deaths (OS) (PE) statistically significant 43 % decrease in DCR
malignant mesothelioma (mMS) - 2nd line (L2) malignant mesothelioma (mMS) - 2nd line (L2)
versus placebo
	nivolumab alone
	CONFIRM unpublished Trials 2018 Apr 18;19(1):233. Lancet Oncol. 2021 Oct 14;S1470-2045(21)00471-X NCT03063450	RCT	malignant mesothelioma (mMS) - 2nd line (L2)	nivolumab	placebo	patients with pleural or peritoneal mesothelioma who have received at least two prior lines of therapy	211 / 111	NA	suggested	suggested 28 % decrease in deaths (OS) (PE) suggested 39 % decrease in progression or deaths (PFS) (PE)
	tremelimumab
	DETERMINE, 2017 Lancet Oncol 2017 Sep;18(9):1261-1273. Clin Transl Sci 2019; 12:450-458 NCT01843374	RCT	malignant mesothelioma (mMS) - 2nd line (L2)	tremelimumab	placebo	patients with unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or two previous systemic treatments for advanced disease	382 / 189	low	inconclusive	inconclusive 8 % decrease in deaths (OS) (PE) suggested 19 % decrease in progression or deaths (PFS)